Navigation Links
CorMedix, Inc. Granted Extension of NYSE-MKT Listing
Date:7/24/2014

iffer materially from projections or estimates due to a variety of important factors, including: the acceptance by the FDA of the protocol for the planned Phase 3 trial for Neutrolin; obtaining regulatory approvals to conduct clinical trials and to commercialize CorMedix's product candidates, including marketing of Neutrolin® in countries other than Germany; the risks associated with the launch of Neutrolin® in Europe and other markets; CorMedix's ability to maintain its listing on the NYSE MKT; the risks and uncertainties associated with CorMedix's ability to manage its limited cash resources; the outcome of clinical trials of CorMedix's product candidates and whether they demonstrate these candidates' safety and effectiveness; CorMedix's ability to enter into and maintain collaborations with third parties for its development and marketing programs; CorMedix's dependence on its collaborations and its license relationships; achieving milestones under CorMedix's collaborations; obtaining additional financing to support CorMedix's research and development and clinical activities and operations; CorMedix's dependence on preclinical and clinical investigators, preclinical and clinical research organizations, manufacturers, sales and marketing organizations, and consultants; and protecting the intellectual property developed by or licensed to CorMedix. These and other risks are described in greater detail in CorMedix's filings with the SEC, copies of which are available free of charge at the SEC's website at www.sec.gov or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law.


'/>"/>
SOURCE CorMedix Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NanoLogix Instructs Third-Party to Prepare US FDA Submittals and is Granted US and Chinese Patents
2. Ultragenyx Granted Orphan Drug Designation for UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7)
3. CE Mark Granted for Wound Spray Based on Sangui Patent
4. Butamax Granted Core Patent for Making Biobutanol and Distillers Grains; Offers Producers Efficient, Low-Cost Production of Biobutanol
5. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
6. ERT Granted Patents on Clinical Trial Participant Compliance
7. Revolutionary Tetrapod Quantum Dot Synthesis US Patent Granted
8. Epizyme Granted First Patent Covering Personalized Therapeutic Drug Candidate E7438
9. Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol"
10. Factor Bioscience Granted First U.S. Patent for RNA-Based Reprogramming Technology
11. Star Scientific Announces Patent Claims to Anatabine Citrate to be Granted by PTO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... Pa. (PRWEB) May 29, 2015 ... Product Solutions with a request to design an ... excess moisture from prescription medications being produced using ... solution that includes a robotic gantry, heat-saving windows, ... and dries trays of 3D-printed pills to exact ...
(Date:5/29/2015)... May 28, 2015 Research and Markets ... Jain PharmaBiotech,s new report "Cytogenetics - Technologies, ... This report deals with cytogenetics in a ... to describe the chromosome structure and identify abnormalities ... biology, it is also referred to as molecular ...
(Date:5/29/2015)... 2015 Seoul Semiconductor (CEO: Chung-hoon ... technology, on May 28th announced that it will ... strengthening its high efficient and high reliable LED ... 2011 Seoul Semiconductor has developed efficient and reliable ... has supplied LEDs for headlamps to global auto ...
(Date:5/28/2015)... 28, 2015 Research ... the addition of Jain PharmaBiotech,s new report ... and Companies" to their offering. ... This report deals with therapeutic drug monitoring, ... patient care by monitoring drug levels in ...
Breaking Biology Technology:New industrial oven with “pill pushing” robotic gantry precisely removes excess moisture from 3D-printed pharmaceuticals 2Global Cytogenetics Market Report 2015-2024 - Technologies, Markets and Companies 2Global Cytogenetics Market Report 2015-2024 - Technologies, Markets and Companies 3Seoul Semiconductor Increases the Global Automotive LED Market Share with its High Efficient and Reliable LEDs for Automotive Lightings 2Global Therapeutic Drug Monitoring Market 2015-2024 2
... Mentice, a leading,supplier of solutions for medical ... Vice President of Global Marketing., Effective from ... coordinate,Mentice,s marketing activities globally from a corporate standpoint., ... years of experience of global,sales, marketing and product ...
... Proteon Therapeutics is,presenting new data today representing ... PRT-201 to enhance outcomes in patients,suffering from ... entitled, "Local Catheter-Directed Elastase Therapy: A Novel,Approach ... made at the 20th,annual Transcatheter Cardiovascular Therapeutics ...
... - New Courses on the Practical Implementation of ... Intra-Operative Imaging, ... worldwide Ziehm Academy Education Program at the beginning of,the year, Ziehm ... training offer. The Ziehm Academy provides,training in line with international standards, ...
Cached Biology Technology:Mentice Appoints Bjorn Larsson as Vice President of Global Marketing 2Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008 2Ziehm Imaging Extends its Training Offer 2Ziehm Imaging Extends its Training Offer 3Ziehm Imaging Extends its Training Offer 4
(Date:5/28/2015)... 2015 Industry analyst firm n-tech Research ... titled "Markets for Self-Healing Materials: 2015-2022." According to the ... vascular systems, biomaterials, relevant shape memory materials and ... billion by 2020. The report is ... smart materials. Other recent n-tech reports have included studies ...
(Date:5/22/2015)... 22, 2015 According to a ... (2D, 3D, Thermal, Emotion, Forensic), by Software (Middleware, Databases), by ... Utilities, Consumer and Home) - Global Forecast to 2020", ... $2.77 Billion in 2015 to $6.19 Billion by 2020, ... 79 market data Tables and   43 Figures spread ...
(Date:5/19/2015)... Fingerprint Cards (FPC) has received an order for ... from one if its module partners. Deliveries are planned to ... the sensors will be used by smartphone manufacturers in ... amount to 740 MSEK to date. In addition to previously ... number of smaller orders not separately communicated amounting to more ...
Breaking Biology News(10 mins):The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... by Mitchell and Kenyon, researchers have confirmed that the ... England, at the beginning of the 20th century. In ... researchers report in the Sept. 18, 2007, Current Biology, ... important because more than 10 percent of people have ...
... Philadelphia, PA, September 17, 2007 Women and men ... Major depressive disorder (MDD) is one of the ... of the most studied. It is already known ... functional changes, associated with MDD and most of todays ...
... A new study published in Nature Genetics on Sunday 16 ... to be due to genetic variation in regions that control ... the protein code. This surprising result comes from a ... of almost 14,000 genes in 270 DNA samples collected for ...
Cached Biology News:Films of Mitchell and Kenyon illuminate lefties' decline in Victorian England 2Women more depressed and men more impulsive with reduced serotonin functioning 2The importance of gene regulation for common human disease 2
Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)...
Recombinant Human CCL21/6Ckine (Mucin Stalk Chimera)...
One-step, microplate or cuvet, colorimetric, detection range 0.78 ug/dL to 65 ug/dL Zn in serum, plasma, urine, saliva etc. Procedure: 10 min....
Zebrafish Ephrin-B2 Biotinylated Affinity Purified PAb...
Biology Products: